Wisconsin-based Shine Medical Technologies has secured $150m in financing from investors for commercialisation of diagnostic and therapeutic isotope technologies, including fusion-based applications, the company said in a statement.

Shine said its existing facility produces the therapeutic medical isotope lutetitum-177 (Lu-177), which is in demand by clinical trial sponsors because of its potential to treat a range of cancers.